DxS Plans PMA For Companion Test To Amgen Colorectal Cancer Drug
This article was originally published in The Gray Sheet
Executive Summary
Personalized medicine company DxS is preparing a PMA application for a companion diagnostic to Amgen's colorectal cancer drug Vectibix, supported by clinical utility data from a recent Amgen-sponsored clinical trial, according to DxS CEO Stephen Little